文献速递眼底病与葡萄膜炎眼外伤

开放性眼球损伤急诊手术结束时玻璃体内注射曲安奈德抑制外伤性增生性玻璃体视网膜病变的随机临床试验

Early use of intravitreal triamcinolone to inhibit traumatic proliferative vitreoretinopathy: a randomised clinical trial.
PubMed 文献 · Br J Ophthalmol · 2024-07-23

单中心、受试者设盲、前瞻性随机对照试验纳入68例Ⅲ区眼球破裂患者,按1:1随机分为对照组(n=34)和TA组(n=34),急诊手术结束时分别注射0.1 mL平衡盐溶液或0.1 mL曲安奈德。10±3天后玻璃体切除术中评估,TA组外伤性增生性玻璃体视网膜病变分级显著轻于对照组(p=0.028),TA组评分9.30±0.82优于对照组6.44±1.06(p=0.036),最终视力改善TA组23眼(92%)vs对照组14眼(63.64%)(p=0.008),视网膜附着率TA组88% vs对照组63.64%(p=0.049)。

要点

  • 急诊手术结束时玻璃体内注射曲安奈德可减轻Ⅲ区眼球破裂患者外伤性增生性玻璃体视网膜病变。
  • TA组最终视力改善23眼(92%)vs对照组14眼(63.64%)(p=0.008)。
  • TA组视网膜附着率88% vs对照组63.64%(p=0.049)。

核心结论

  • 开放性眼球损伤早期玻璃体内注射曲安奈德有效减轻外伤性增生性玻璃体视网膜病变、提高手术成功率并改善视力预后。

研究设计与样本

  • 单中心、受试者设盲、前瞻性随机对照临床试验,纳入68例Ⅲ区眼球破裂患者,按1:1随机分为对照组(n=34)和TA组(n=34)。
  • TA组急诊手术结束时注射0.1 mL曲安奈德,对照组注射0.1 mL平衡盐溶液。
  • 主要结局为10±3天后玻璃体切除术中评估外伤性增生性玻璃体视网膜病变,次要结局包括玻璃体切除术后6个月的视力、视网膜附着率、黄斑附着率、增生性玻璃体视网膜病变复发率和副作用。

主要发现

  • 玻璃体切除术中对照组外伤性增生性玻璃体视网膜病变分级显著重于TA组(p=0.028)。
  • TA组外伤性增生性玻璃体视网膜病变评分9.30±0.82显著优于对照组6.44±1.06(p=0.036)。
  • 最终视力改善TA组23眼(92%)vs对照组14眼(63.64%)(p=0.008)。
  • 视网膜附着率TA组88% vs对照组63.64%(p=0.049)。
  • 两组黄斑复位率和增生性玻璃体视网膜病变复发率无显著差异(p=0.215、0.191);TA组急诊手术后1眼出现暂时性眼压升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To evaluate the efficacy and safety of intravitreal triamcinolone acetonide (TA) injection at the end of emergency surgery for open globe injury (OGI) to suppress traumatic proliferative vitreoretinopathy (TPVR). METHODS: A single-centre, participant-masked, prospective, randomised controlled clinical trial. A total of 68 globe rupture patients with zone III were randomised to the control group (n=34) or the TA group (n=34) in 1:1 allocation ratio. Patients were treated with 0.1 mL TA in the TA group and 0.1 mL balanced salt solution in the control group at the end of emergency surgery. The primary outcome was the assessment of TPVR during vitrectomy 10±3 days later. Secondary outcomes included visual acuity (VA), retinal attachment rate, macular attachment rate, proliferative vitreoretinopathy (PVR) recurrent rate, side effects 6 months after vitrectomy. RESULTS: During vitrectomy, the TPVR grade of the control group was significantly more severe than the TA group (p=0.028). The TPVR score was significantly better in the TA group (9.30±0.82) than in the control group (6.44±1.06) (p=0.036). The final VA improved in 23 eyes (92%) in the TA group and in 14 eyes (63.64%) in the control group (p=0.008). The retinal attachment rates were 88% and 63.64% in the TA and control group, respectively (p=0.049). The two groups showed no significant difference in macular repositioning and PVR recurrent rate (p=0.215, 0.191). Temporary intraocular pressure elevation occurred in one eye in the TA group after emergency surgery. CONCLUSIONS: Early intravitreal TA injection for OGI effectively reduces TPVR, increases surgical success and improves visual prognosis.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Guo H, Yu J, He T, et al. Early use of intravitreal triamcinolone to inhibit traumatic proliferative vitreoretinopathy: a randomised clinical trial. Br J Ophthalmol. 2024. PMID: 38041678. doi:10.1136/bjo-2023-324318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。